Join us at the 11th Global
Pharmaceutical Quality Summit 2026
Join us at the 11th Global
Pharmaceutical Quality Summit 2026
Experience Leucine AI .
‍
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Cleaning Validation
Cleaning Validation
View Detailed Analysis

Analytics Overview

172
Form 483s Issued
35
483s converted to WL
227
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
08 Apr 2026
Pharmaneek Inc
Drugs
27 Mar 2026
Bentley Laboratories LLC
Drugs
23 Mar 2026
Dr. J Skinclinic, Inc
Drugs
20 Mar 2026
Bora Pharmaceuticals Injectables Inc
Drugs
20 Mar 2026
Eosera, Inc.
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
17
6
Anastasia M Shields
12
6
Joseph A Piechocki
10
4
Pratik S Upadhyay
8
1
Arsen Karapetyan
7
1
TITLE/ COMPANY Issue Date Status Details
Hazardous drugs were produced without providing adequate containment
Pharmaneek Inc
08 Apr 2026 Normal Justification: Cleaning validation is specifically needed as current practices fail to remove hazardous residues.
Excerpt: The current cleaning process is deficient and does not provide assurance that drug residue is adequately removed.
View Details
Written procedures are not established and followed for the cleaning and maintenance of equipment
Bentley Laboratories LLC
27 Mar 2026 Normal Justification: The observation explicitly mentions deficiencies in the Cleaning Validation process, citing missing swab sample collections and incomplete validation documentation.
Excerpt: Cleaning Validation (CV) conducted for (b) (4) is deficient; swab samples not collected as per procedure.
View Details
Written procedures are not established for the cleaning and maintenance of equipment, including utensils
Dr. J Skinclinic, Inc
23 Mar 2026 Normal Justification: Cleaning Validation ensures that cleaning procedures for shared equipment prevent cross-contamination and meet safety standards.
Excerpt: Your firm failed to establish cleaning validation to verify that current cleaning practices for (b)(4) shared equipment, that could prevent the cause of cross contamination.
View Details
Written procedures are not established for the cleaning and maintenance of equipment
Eosera, Inc.
20 Mar 2026 Normal Justification: Cleaning validation is directly related because deficiencies in protocol and testing compromise the efficacy of cleaning.
Excerpt: The cleaning validation study protocol # QA.VA.106 is deficient, lacking microbiological examination documentation and specific product documentation.
View Details
Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
Bora Pharmaceuticals Injectables Inc
20 Mar 2026 Normal Justification: Inadequate cleaning verification directly impacts cleaning validation by failing to assure equipment cleanliness.
Excerpt: Cleaning verification is inadequate and does not provide sufficient evidence... swab sampling is limited... no rinse samples are collected.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Cleaning Validation

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Cleaning Validation

Overview

As the FDA continues to enforce high standards, the volume of Form 483s and Warning Letters associated with cleaning validation has shown notable fluctuations. These trends point to the rising importance of well-documented procedures, proactive risk assessments, and a thorough understanding of residue limits. Leveraging real-time analytics can help predict and prevent potential compliance gaps.

172
Form 483s Issued
35
483s converted to WL
227
Total Observation
Form 483s Issued
+74 from last period

Failure to address these fluctuations can lead to repeated observations, heavier scrutiny in future inspections, or even warning letters. Leveraging real‐time analytics, like CLEEN’s location‐based residue monitoring, can help predict and prevent potential compliance gaps before they escalate.

CLEEN Logbook Graphic
Stay Ahead of FDA Enforcement
Avoid common pitfalls by standardizing cleaning protocols and tracking HBEL-based residue levels in real time.
Explore CLEEN

Recent Form 483s & Warning Letters

Recent observations reveal that many 483s stem from incomplete cleaning records, insufficient justifications, or failure to maintain continuous monitoring. The examples below highlight how quickly small oversights can escalate, helping you benchmark your own protocols and identify potential gaps before an inspection.
‍

If you want to eliminate guesswork and reduce manual documentation errors, discover how CLEEN automates cleaning validation - offering real‐time residue tracking, automated SOP enforcement, and streamlined reporting for faster, more accurate compliance.

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
08 Apr 2026
Pharmaneek Inc
Drugs
27 Mar 2026
Bentley Laboratories LLC
Drugs
23 Mar 2026
Dr. J Skinclinic, Inc
Drugs
20 Mar 2026
Bora Pharmaceuticals Injectables Inc
Drugs
20 Mar 2026
Eosera, Inc.
Drugs

Top FDA Investigators

Certain FDA investigators routinely focus on specific cleaning validation issues, such as inadequate residue monitoring, data integrity lapses, and missing risk-based assessments. Understanding their patterns can help you anticipate where they’ll look first—and ensure you have the right documentation and evidence on hand.
‍

A centralized platform like CLEEN consolidates all your cleaning validation data—ranging from SOP compliance and residue logs to deviation handling—so you’re fully prepared to demonstrate compliance whenever these investigators arrive.

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
17
6
Anastasia M Shields
12
6
Joseph A Piechocki
10
4
Pratik S Upadhyay
8
1
Arsen Karapetyan
7
1
Stay Ahead of FDA Enforcement
Avoid common pitfalls by standardizing cleaning protocols and tracking HBEL-based residue levels in real time.
Explore CLEEN

Key Observations

FDA Cleaning Validation citations are often due to manual documentation errors, inadequate validation protocols, and inconsistent residue monitoring. The examples below illustrate how these lapses manifest during inspections—understanding them can help you pinpoint and correct similar issues before they lead to costly 483s or Warning Letters.
TITLE/ COMPANY Issue Date Status Details
Hazardous drugs were produced without providing adequate containment
Pharmaneek Inc
08 Apr 2026 Normal Justification: Cleaning validation is specifically needed as current practices fail to remove hazardous residues.
Excerpt: The current cleaning process is deficient and does not provide assurance that drug residue is adequately removed.
View Details
Written procedures are not established and followed for the cleaning and maintenance of equipment
Bentley Laboratories LLC
27 Mar 2026 Normal Justification: The observation explicitly mentions deficiencies in the Cleaning Validation process, citing missing swab sample collections and incomplete validation documentation.
Excerpt: Cleaning Validation (CV) conducted for (b) (4) is deficient; swab samples not collected as per procedure.
View Details
Written procedures are not established for the cleaning and maintenance of equipment, including utensils
Dr. J Skinclinic, Inc
23 Mar 2026 Normal Justification: Cleaning Validation ensures that cleaning procedures for shared equipment prevent cross-contamination and meet safety standards.
Excerpt: Your firm failed to establish cleaning validation to verify that current cleaning practices for (b)(4) shared equipment, that could prevent the cause of cross contamination.
View Details
Written procedures are not established for the cleaning and maintenance of equipment
Eosera, Inc.
20 Mar 2026 Normal Justification: Cleaning validation is directly related because deficiencies in protocol and testing compromise the efficacy of cleaning.
Excerpt: The cleaning validation study protocol # QA.VA.106 is deficient, lacking microbiological examination documentation and specific product documentation.
View Details
Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
Bora Pharmaceuticals Injectables Inc
20 Mar 2026 Normal Justification: Inadequate cleaning verification directly impacts cleaning validation by failing to assure equipment cleanliness.
Excerpt: Cleaning verification is inadequate and does not provide sufficient evidence... swab sampling is limited... no rinse samples are collected.
View Details

By standardizing cleaning protocols, integrating real-time residue checks, and automating documentation, you can prevent these common pitfalls. Many pharma teams use CLEEN’s all-in-one platform to streamline every step—from SOP enforcement to final verification—ensuring consistent compliance and fewer inspection surprises.

Ensure FDA Compliance With an Automated Cleaning Validation Approach
Reduce the risk of escalating 483s with real-time residue tracking and robust documentation.
Explore CLEEN
CLEEN Illustration

Frequently Asked Questions

What sampling methods are used in Cleaning Validation?

  • Swab Sampling: A direct method for assessing residue on equipment surfaces.
  • Rinse Sampling: Collecting wash water to detect dissolved residues.
  • Direct Contact Testing: Measuring residue directly from the equipment surface.

Pro Tip: Platforms like CLEEN can log sampling results automatically and generate real‐time residue analysis reports, reducing manual errors.
‍

‍

‍


‍

What acceptance criteria should be set for physical, chemical, and microbial residues?

  • Toxicity and Safety Limits (based on HBEL—Health‐Based Exposure Limits).
  • Solubility and Cleanability of residues.
  • Regulatory Guidelines for microbial contamination and endotoxin levels.

Toxicity and Safety Limits (based on HBEL—Health‐Based Exposure Limits).

Pro Tip: With CLEEN’s built‐in HBEL calculator, you can quickly set residue limits tailored your facilitates product and equipment type.
‍

How can automation improve Cleaning Validation processes?

  • Standardizing Cleaning Validation protocols, reducing human error.
  • Digitally tracking residue limits and validation status for audit readiness.
  • Integrating with LIMS and manufacturing execution systems (MES) for real‐time compliance monitoring.

Pro Tip: CLEEN’s automated workflows enforce SOP compliance, send alerts for deviations, and offer integrated reporting that keeps you inspection‐ready at all times.
‍

Are there cost-effective strategies for managing Cleaning Validation in multi-product facilities?

  • Implement standardized cleaning procedures across multiple products.
  • Use validated residue monitoring tools to optimize cleaning cycles.
  • Automate Cleaning Validation documentation and reporting for regulatory ease.

Pro Tip: By leveraging CLEEN’s centralized platform for each product batch, you can reduce duplication, unify records, and lower overall operational costs.
‍

Have More Questions on Cleaning Validation?

Explore how CLEEN automates sampling, residue limit calculations, and compliance reporting for a hassle‐free validation process.
Learn More About CLEEN

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources